Skip to content

Annexon ANNX Non-Cash Lease Expense

Non-Cash Lease Expense at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$44K-58.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$480K+4.3%
Vera Therapeutics logo
Vera TherapeuticsVERA
$116K-74.6%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$2.23M+5.0%
Glaukos logo
GlaukosGKOS
$1.09M+0.6%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's non-cash lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's non-cash lease expense?
Annexon (ANNX) reported non-cash lease expense of $418K in Q1 2026.
How has Annexon's non-cash lease expense changed year-over-year?
Annexon's non-cash lease expense increased by 16.4% year-over-year, from $359K to $418K.
What is the long-term trend for Annexon's non-cash lease expense?
Over 4 years (2021 to 2025), Annexon's non-cash lease expense has grown at a 4.5% compound annual growth rate (CAGR), from $1.27M to $1.52M.
What does non-cash lease expense mean?
Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.